← All trials
NCT04900454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- May 25, 2021
- Last posted
- Aug 10, 2021
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Deverra Therapeutics, Inc.Lead sponsor
- University of WashingtonOverall official - principal investigator
- University of WashingtonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.